End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
132.3 CHF | -2.68% | -5.49% | +0.68% |
05-28 | Sector Update: Health Care Stocks Fall Late Afternoon | MT |
05-28 | Sector Update: Health Care Stocks Retreat Tuesday Afternoon | MT |
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
Weaknesses
- According to forecast, a sluggish sales growth is expected for the next fiscal years.
- The company's earnings growth outlook lacks momentum and is a weakness.
- With an enterprise value anticipated at 3.85 times the sales for the current fiscal year, the company turns out to be overvalued.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+0.68% | 354B | - | ||
+38.59% | 727B | C+ | ||
+15.66% | 328B | B- | ||
+0.24% | 277B | C+ | ||
+13.47% | 243B | B+ | ||
+7.35% | 205B | B- | ||
-6.42% | 203B | A+ | ||
+4.23% | 164B | C+ | ||
-1.70% | 164B | C+ | ||
-1.31% | 122B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- JNJ Stock
- 000943981 Stock
- Ratings Johnson & Johnson